Vaccinations for Neuroinfectious Disease: A Global Health Priority

Neurotherapeutics

Volumn 13, Issue 3, 2016, Pages 562-570

  Leibovitch, Emily C ^a,b   Jacobson, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

CNS infections; Encephalitis; Meningitis; Neuroinfectious; Neuroinvasive; Vaccines

Indexed keywords

DENGUE VACCINE; FUNGUS VACCINE; HERPES VACCINE; JAPANESE ENCEPHALITIS VACCINE; MALARIA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; RABIES VACCINE; TICK BORNE ENCEPHALITIS VACCINE; VACCINE; VIRUS VACCINE; WEST NILE VACCINE; YELLOW FEVER VACCINE; ZIKA VIRUS VACCINE;

ALPHAVIRUS; CENTRAL NERVOUS SYSTEM INFECTION; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; DENGUE VIRUS; EASTERN EQUINE ENCEPHALITIS VIRUS; FILOBASIDIELLA; FLAVIVIRUS; HERPESVIRIDAE; HUMAN; JAPANESE ENCEPHALITIS VIRUS; MEASLES VIRUS; NEISSERIA MENINGITIDIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM; PRIORITY JOURNAL; RABIES VIRUS; REVIEW; TICK BORNE ENCEPHALITIS VIRUS; VACCINATION; VACCINE PRODUCTION; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; WESTERN EQUINE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS; ZIKA VIRUS; ZOONOSIS; ALPHAVIRUS INFECTIONS; ANIMAL; FLAVIVIRUS INFECTIONS; GLOBAL HEALTH; HERPESVIRIDAE INFECTIONS; IMMUNOLOGY; MASS IMMUNIZATION; MEASLES; PATHOGENICITY; VIROLOGY; ZOONOSES;

ALPHAVIRUS INFECTIONS; ANIMALS; CRYPTOCOCCUS; FLAVIVIRUS INFECTIONS; GLOBAL HEALTH; HERPESVIRIDAE INFECTIONS; HUMANS; MASS VACCINATION; MEASLES; NEISSERIA MENINGITIDIS; PLASMODIUM; VIRAL VACCINES; ZOONOSES;

EID: 84976510236     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-016-0453-3     Document Type: Review

References (76)

1. Andre, F.E. et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ 86, 140-146 (2008).
2. Nath, A. & Tyler, K.L. Novel approaches and challenges to treatment of central nervous system viral infections. Ann Neurol 74, 412-422 (2013).
3. Tracey, J. Syndromic Approach to Neuroinfectious disease (ed. Kelly D Flemming, L.K.J.) (Oxford University Press, 2015).
4. John, C.C. et al. Global research priorities for infections that affect the nervous system. Nature 527, S178-S186 (2015).
5. Go, Y.Y., Balasuriya, U.B. & Lee, C.K. Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res 3, 58-77 (2014).
6. Fauci, A.S. & Morens, D.M. Zika Virus in the Americas—yet another arbovirus threat. N Engl J Med 374, 601-604 (2016).
7. Liang, H., Lee, M. & Jin, X. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol 13, 36-46 (2016).
8. Wahala, W.M., Kraus, A.A., Haymore, L.B., Accavitti-Loper, M.A. & de Silva, A.M. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392, 103-113 (2009).
9. Erra, E.O. & Kantele, A. The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis. Expert Rev Vaccines 14, 1167-1179 (2015).
10. Hills, S.L., Rabe, I.B., Fischer, M. Japanese Encephalitis, Chapter 3: Infectious Diseases Related to Travel. http://www.cdc.gov (2015).
11. Vaccine-preventable diseases and vaccines. WHO International Travel and Health publication (2015).
12. Heinz, F.X. et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis 19, 69-76 (2013).
13. Zajkowska, J. et al. Fatal outcome of tick-borne encephalitis—a case series. Neurol Neurochir Pol 45, 402-6 (2011).
14. Veje, M. et al. Tick-Borne encephalitis sequelae at long-term follow-up: a self-reported case-control study. Acta Neurol Scand (2016).
15. Kunze, U. & Kunze, M. The Austrian vaccination paradox: tick-borne encephalitis vaccination versus influenza vaccination. Cent Eur J Public Health 23, 223-226 (2015).
16. Karunamoorthi, K. Yellow fever encephalitis: an emerging and resurging global public health threat in a changing environment (ed. S., T.) (2013).
17. Butler, D. Fears rise over yellow fever's next move. Nature 532, 155-156 (2016).
18. Meeting of the Strategic Advisory Group of Experts on immunization, April 2013—conclusions and recommendations. Wkly Epidemiol Rec 88, 201-206 (2013).
19. Li, S. et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 15, 195-204 (2014).
20. Petrovsky, N. et al. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 87, 10324-10333 (2013).
21. Lobigs, M. & Diamond, M.S. Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines 11, 177-187 (2012).
22. Barrett, P.N., Mundt, W., Kistner, O. & Howard, M.K. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8, 607-618 (2009).
23. Hotez, P.J. Zika in the United States of America and a Fateful 1969 Decision. PLoS Negl Trop Dis 10, e0004765 (2016).
24. Whitehead, S.S. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine? Expert Rev Vaccines 15, 509-517 (2016).
25. Wilder-Smith, A. & Yoon, I.K. Edging closer towards the goal of a dengue vaccine. Expert Rev Vaccines 15, 433-435 (2016).
26. Broutet, N. et al. Zika Virus as a Cause of Neurologic Disorders. N Engl J Med (2016).
27. Tripp, R.A. & Ross, T.M. Development of a Zika vaccine. Expert Rev Vaccines, 1-3 (2016).
28. Pastula, D.M., Smith, D.E., Beckham, J.D. & Tyler, K.L. Four emerging arboviral diseases in North America: Jamestown Canyon, Powassan, chikungunya, and Zika virus diseases. J Neurovirol (2016).
29. Petersen, L.R., Jamieson, D.J., Powers, A.M. & Honein, M.A. Zika virus. N Engl J Med (2016).
30. Schuler-Faccini, L. et al. Possible association between Zika virus infection and microcephaly—Brazil, 2015. MMWR Morb Mortal Wkly Rep 65, 59-62 (2016).
31. Malkki, H. CNS infections: Zika virus infection could trigger Guillain-Barré syndrome. Nat Rev Neurol 12, 187 (2016).
32. Cao-Lormeau, V.M. et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis 20, 1085-1086 (2014).
33. Carteaux, G. et al. Zika virus associated with meningoencephalitis. N Engl J Med (2016).
34. Mecharles, S. et al. Acute myelitis due to Zika virus infection. Lancet (2016).
35. Bell, T.M., Field, E.J. & Narang, H.K. Zika virus infection of the central nervous system of mice. Arch Gesamte Virusforsch 35, 183-193 (1971).
36. Palacios, R., Poland, G.A. & Kalil, J. Another emerging arbovirus, another emerging vaccine: targeting Zika virus. Vaccine (2016).
37. Zacks, M.A. & Paessler, S. Encephalitic alphaviruses. Vet Microbiol 140, 281-286 (2010).
38. Guerbois, M. et al. IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety. PLoS Negl Trop Dis 7, e2197 (2013).
39. Molina, O.M. et al. [Venezuelan equine encephalitis. 1995 outbreak: clinical profile of the case with neurologic involvement]. Rev Neurol 29, 296-298 (1999).
40. Paessler, S. et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic. J Virol 77, 9278-9286 (2003).
41. Phillips, A.T. et al. Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses. J Virol 88, 1771-1780 (2014).
42. Smalley, C., Erasmus, J.H., Chesson, C.B. & Beasley, D.W. Status of research and development of vaccines for chikungunya. Vaccine (2016).
43. Chandak, N.H. et al. Neurological complications of Chikungunya virus infection. Neurol India 57, 177-180 (2009).
44. De Benedictis, P. et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol Med (2016).
45. Kalita, J. et al. Paralytic rabies: MRI findings and review of literature. Neurol India 62, 662-664 (2014).
46. Hampson, K. et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis 9, e0003709 (2015).
47. Sanders, B.P. et al. Cold-Adapted viral attenuation (CAVA): highly temperature sensitive polioviruses as novel vaccine strains for a next generation inactivated poliovirus vaccine. PLoS Pathog 12, e1005483 (2016).
48. Campbell, H., Andrews, N., Brown, K.E. & Miller, E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 36, 1334-1348 (2007).
49. Gualberto, F.A. et al. Fulminant encephalitis associated with a vaccine strain of rubella virus. J Clin Virol 58, 737-740 (2013).
50. Subacute sclerosing panencephalitis and measles vaccination. Wkly Epidemiol Rec (2006).
51. Phadke, V.K., Bednarczyk, R.A., Salmon, D.A. & Omer, S.B. Association between vaccine refusal and vaccine-preventable diseases in the United States: a review of measles and pertussis. JAMA 315, 1149-1158 (2016).
52. George, B.P., Schneider, E.B. & Venkatesan, A. Encephalitis hospitalization rates and inpatient mortality in the United States, 2000–2010. PLoS One 9, e104169 (2014).
53. Ogata, M., Fukuda, T. & Teshima, T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant 50, 1030-1036 (2015).
54. Tesini, B.L., Epstein, L.G. & Caserta, M.T. Clinical impact of primary infection with roseoloviruses. Curr Opin Virol 9, 91-96 (2014).
55. Connelly, K.P. & DeWitt, L.D. Neurologic complications of infectious mononucleosis. Pediatr Neurol 10, 181-184 (1994).
56. Weinberg, A., Li, S., Palmer, M. & Tyler, K.L. Quantitative CSF PCR in Epstein–Barr virus infections of the central nervous system. Ann Neurol 52, 543-548 (2002).
57. Johnston, C., Koelle, D.M. & Wald, A. HSV-2: in pursuit of a vaccine. J Clin Invest 121, 4600-4609 (2011).
58. Gagliardi, A.M., Andriolo, B.N., Torloni, M.R. & Soares, B.G. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 3, CD008858 (2016).
59. Science, M. et al. Central nervous system complications of varicella-zoster virus. J Pediatr 165, 779-785 (2014).
60. Johnston, C., Gottlieb, S.L. & Wald, A. Status of vaccine research and development of vaccines for herpes simplex virus prepared for WHO PD-VAC. Vaccine (2016).
61. Cohen, J.I., Mocarski, E.S., Raab-Traub, N., Corey, L. & Nabel, G.J. The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine 31(Suppl. 2), B194-B196 (2013).
62. Smith, C. & Khanna, R. The development of prophylactic and therapeutic EBV vaccines. Curr Top Microbiol Immunol 391, 455-473 (2015).
63. Gianchecchi, E., Torelli, A., Piccini, G., Piccirella, S. & Montomoli, E. Neisseria meningitidis infection: who, when and where? Expert Rev Anti Infect Ther 13, 1249-1263 (2015).
64. Folaranmi, T. et al. Use of serogroup B meningococcal vaccines in persons aged >/=10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 64, 608-612 (2015).
65. Park, B.J. et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525-530 (2009).
66. Wilson, J.W. Fungal infections of the central nervous system (Mayo Foundation for Medical Education and Research, 2015).
67. Nanjappa, S.G. & Klein, B.S. Vaccine immunity against fungal infections. Curr Opin Immunol 28, 27-33 (2014).
68. Wozniak, K.L., Young, M.L. & Wormley, F.L., Jr. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin Vaccine Immunol 18, 717-723 (2011).
69. Rella, A. et al. Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. Front Microbiol 6, 836 (2015).
70. Dieye, Y. et al. Cytokine response during non-cerebral and cerebral malaria: evidence of a failure to control inflammation as a cause of death in African adults. PeerJ 4, e1965 (2016).
71. Malaria vaccine: WHO position paper-January 2016. Wkly Epidemiol Rec 91, 33-51 (2016).
72. Gosling, R. & von Seidlein, L. The future of the RTS,S/AS01 malaria vaccine: an alternative development plan. PLoS Med 13, e1001994 (2016).
73. Hora, R., Kapoor, P., Thind, K.K. & Mishra, P.C. Cerebral malaria - clinical manifestations and pathogenesis. Metab Brain Dis 31, 225-237 (2016).
74. Long, C.A. & Zavala, F. Malaria vaccines and human immune responses. Curr Opin Microbiol 32, 96-102 (2016).
75. Morrison, C. Landmark green light for Mosquirix malaria vaccine. Nat Biotechnol 33, 1015-1016 (2015).
76. Kardani, K., Bolhassani, A. & Shahbazi, S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine 34, 413-423 (2016).